Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
about
Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor ConsortiumCancer therapies utilizing the camptothecins: a review of the in vivo literatureCamptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
P2860
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phase I and pharmacokinetic st ...... : a novel camptothecin analog.
@ast
Phase I and pharmacokinetic st ...... : a novel camptothecin analog.
@en
type
label
Phase I and pharmacokinetic st ...... : a novel camptothecin analog.
@ast
Phase I and pharmacokinetic st ...... : a novel camptothecin analog.
@en
prefLabel
Phase I and pharmacokinetic st ...... : a novel camptothecin analog.
@ast
Phase I and pharmacokinetic st ...... : a novel camptothecin analog.
@en
P2093
P1476
Phase I and pharmacokinetic st ...... : a novel camptothecin analog.
@en
P2093
M P Ducharme
R De Jager
P304
P356
10.1200/JCO.2001.19.5.1493
P407
P577
2001-03-01T00:00:00Z